KRT14

(redirected from cytokeratin 14)

KRT14

A gene on chromosome 17q12-q21 that encodes a type-I intermediate filament keratin, which typically forms a heterotetramer with KRT5 (type-II) keratins that together form the cytoskeleton of epithelial cells.

Molecular pathology
KRT14 mutations are associated with epidermolysis bullosa simplex.
References in periodicals archive ?
2), actin, vimentin and cytokeratin 14 and negative for cytokeratin 18 and 19.
The low-grade fibromatosis-like spindle cell carcinoma tumor cells entrap normal breast glandular structures (A), and are highlighted by cytokeratin 14 (B), vimentin (C), and p63 (D) immunohistochemical stains (hematoxylin-eosin, original magnification X20 [A]; original magnification X20 [B through D]).
They identified one protein, cytokeratin 14, or K14, that was present in almost all leader cells but was very rare in the noninvasive parts of the tumour.
In myoepithelioma, tumor cells stain positive for S-100 protein, alpha-SMA, muscle-specific actin, vimentin, pankeratin, cytokeratin 7, cytokeratin 14, GFAP, EMA, and calponin.
Odontomas express cytokeratin 14, which is absent in advanced amelogenesis, and cytokeratin 7, which is present in Hertwig root sheath and stellate reticulum.
9) Cytokeratin 14 (CK14) and cytokeratin 17 (CK17) have both been reported as positive immunostains for BCC, (10) although CK14 has not been studied in BCCm.
Cytokeratin 14 stains normal basal keratinocytes of the epidermis (10,34) as well as follicular outer root sheath epithelium.
Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray.
the utility of anti-mitochondrial, caveolin-1, CD63 and cytokeratin 14 antibodies in the differential diagnosis.
By immunohistochemical evaluation, adenoid cystic/ basal cell carcinomas of the prostate are usually positive for high-molecular-weight keratin (clone 34[beta]E12) and cytokeratin 14, at least focally in all cases reported (Figures 3 and 4).
The antibodies used included monoclonal antibodies against cytokeratin (AE1/AE3) and cytokeratin 14 (BioGenex, San Ramon, Calif), epithelial membrane antigen, vimentin, desmin, actin (HHF35), smooth muscle actin, glial fibrillary acidic protein, and CD34 (Dakopatts a/s, Glostrup, Denmark).